论文部分内容阅读
目的：研究ｎｍ２３Ｈ１、Ｐ１８５、Ｐ２１和Ｐ５３在卵巢癌中的表达及用于判断患者预后的价值。方法：用单克隆抗体、免疫组化技术测定７４例原发性卵巢癌患者中上述癌蛋白的表达。结果：ｎｍ２３Ｈ１、Ｐ１８５、Ｐ２１和Ｐ５３的阳性表达率分别是２９．７％、７４．３％、６３．５％和６７．５％，各种癌蛋白之间的表达无相关性。患者生存率的单因素分析显示随Ｐ２１表达增高而下降；多因素分析显示Ｐ５３是独立的患者预后因素，而ｎｍ２３Ｈ１、Ｐ１８５和Ｐ２１与患者生存率无关，临床分期和残留灶大、小是其它独立的患者预后因素。结论：在上皮性卵巢癌中Ｐ５３表达，临床分期和残留灶大、小具有独立的判断患者预后的价值
Objective: To study the expression of nm23H1, P185, P21 and P53 in ovarian cancer and its value in judging the prognosis of patients. Methods: The expression of the aforementioned oncoproteins in 74 patients with primary ovarian cancer was determined by monoclonal antibodies and immunohistochemistry. RESULTS: The positive rates of nm23H1, P185, P21, and P53 were 29.7%, 74.3%, 63.5%, and 67.5%, respectively, and there was no correlation between the expression of various oncoproteins. Univariate analysis of patient survival rates showed a decline with increased expression of P21; multivariate analysis showed that P53 was an independent prognostic factor, whereas nm23H1, P185, and P21 were not associated with survival, and clinical staging and residual lesions were large or small. Patient prognosis factors. CONCLUSIONS: P53 expression, clinical stage, and residual lesions in epithelial ovarian cancer have independent value in judging the prognosis of patients.